

Risk of Bias Assessment in Non-Randomized Studies of Interventions for Premenstrual Syndrome: A Systematic Review

Hadi Tehfe; M.D.¹, Ryan Chow; M.D.¹, Sophie Li; M.D.¹, Patrick Kim; M.D.², Saif Samari; M.D.², Lamia Hayawi; M.D.³, Richard Webster; M.D.³, Nadya Ben Fadel; M.D.⁴

1 Faculty of Medicine, University of Ottawa, Ottawa, Canada

2 Faculty of Medicine, McMaster University, Hamilton, Canada

3 Clinical Research Unit, Children's Hospital of Eastern Ontario, Ottawa, Canada

4 Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Canada

Received July 2021; Revised and accepted April 2022

Abstract

Objective: Premenstrual syndrome (PMS) is a very prevalent condition that affects premenopausal women and can result in monthly debilitating emotional and physical symptoms. The objective of this systematic review was to determine which predictive factors were associated with an increased amount of bias in non-randomized studies (NRSs) of PMS.

Materials and methods: A search of the EMBASE and Medline electronic databases was completed from January 1, 2010 to December 2021. The methodological quality of the included studies was independently evaluated and critically appraised using the Risk of Bias in Non-Randomized Studies - of Interventions (ROBINS-1) tool. Associations of different factors with the risk of bias levels were assessed using a univariate logistic regression. Odds ratio and 95% confidence interval (CI) were reported.

Results: Of the 1668 studies, 38 were determined to be eligible for inclusion. The ROBINS-1 tool identified that 12 studies were of low/moderate risk of bias (31.6%) and 26 were of serious/critical risk (68.4%). Evidence of relationships between the ROBINS-1 score and impact factor (OR=0.20; 95% CI, 0.07 to 0.57; p= 0.003) and number of authors (OR=0.65; 95% CI, 0.43 to 0.99; p= 0.046) were identified, whereas no relationships were found with the number of citations, the sample size, the funding type, or the conflict-of-interest statement.

Conclusion: The systematic review concludes that the methodological rigor of non-randomized studies of PMS can vary, with fewer authors and a lower impact factor showing evidence of association with a decreased quality of evidence.

Keywords: Premenstrual Syndrome; Non-Randomized Controlled Trials; Systematic Review

Introduction

Premenstrual syndrome (PMS), a condition that occurs monthly during the luteal phase of the

menstrual cycle, is characterized by a series of recurrent emotional and physical symptoms (1). Typical symptoms of PMS include anger, irritability, depression, abdominal bloating, tenderness in the breasts, fatigue, and anxiety (2). These symptoms can be further exasperated in the severe form of PMS,

Correspondence:

Dr. Hadi Tehfe

Email: [hte hf091@uottawa.ca](mailto:htehf091@uottawa.ca)



Copyright © 2022 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (<https://creativecommons.org/licenses/by-nc/4.0/>).

Noncommercial uses of the work are permitted, provided the original work is properly cited.

premenstrual dysphoric disorder (PMDD) (2). PMS first appears in women post-puberty and can substantially impair work, social and family relationships until its resolution with menopause (3). Although the global prevalence of PMS is estimated to be 30-40% (3-8% for PMDD), a 2017 cross-sectional study published by Jarosz et al. revealed that 99% of young multi-ethnic Canadian women suffer from some type of premenstrual symptom (3-4). However, the prevalence of PMS and the impacts of its debilitating symptoms are often under-recognized by many laypeople, workers, governmental organizations and practicing healthcare professionals (3). Even Halbreich et al. noted recently (2004) that new diagnostic criteria for PMS are desperately needed (5). This was attributed to the lack of universal consensus on the nature of PMDD and PMS and the lack of interdisciplinary and universal acceptance of diagnostic criteria at the time (5).

Evidence of the effectiveness of PMS interventions is predominantly from non-randomized studies (NRSs). Many studies on PMS interventions use NRSs as they aim to study the effects between a certain patient group — women who suffer from PMS — and a control. Consequently, the existing evidence does not use randomization to eliminate systematic baseline differences between experimental and control groups (6). Potential biases are thus greater for NRSs as compared to RCTs (7) and NRSs have been found to overestimate the effect of intervention as compared to the results from similar RCTs (8). Fortunately, not all NRSs suffer from a significant amount of bias, and when carefully designed yield valid results (9). Although a wide range of systematic reviews has been conducted on PMS, no studies have explicitly investigated the presence of bias; this is a vital addition where evidence is predominately from non-randomized studies. Furthermore, no systematic reviews of NRSs have yet to be conducted in the context of PMS. Only through contextualizing the evidence and its bias for intervention into PMS can clinicians and policy decision makers confidently act on these data.

The objective of this systematic review is to determine which factors are associated with an increased amount of bias in non-randomized studies of PMS. These predictors include the impact factor of the journal, the number of citations, the source of funding, and the authors' conflicts of interest statement. The *a priori* hypothesis for this systematic review is that the authors' conflicts of interest, a lower journal impact

factor, a lower number of citations, and studies that received funding from industry sources will be associated with a greater risk of bias.

Materials and methods

The protocol of this systematic review was conducted according to the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (10). The study was further pre-registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the reference number (CRD42020218896).

Search Strategy and Selection criteria: A comprehensive search of the EMBASE and Medline electronic databases was completed from January 1, 2010 to December 2021. The search terms used included “premenstrual syndrome”, “premenstrual tension”, “PMS”, “treat*”, “therap*”, “interven*”, “surg*”, “drug*”, “perscri*”, and “medicat*”. The search strategy was developed with the assistance of a medical librarian and is available in the appendix (Appendix S1).

Publications based on the search strategy were uploaded to Covidence; a systematic review software (www.covidence.org). The abstracts and titles of all papers were screened independently by four reviewers (R.C, S.L, S.S, P.K.), each two in duplicate. Disagreements between reviewers were resolved through a discussion with the primary author (H. T.) to confirm eligibility. To be included in this systematic review, publications were required to meet the following inclusion criteria: (1) non-randomized studies (cohort, case-control, and quasi-randomized studies); (2) trials relevant to PMS (self-identified in the title or abstract); (3) interventions involving a treatment, procedure or drug. Articles were excluded if they met the following exclusion criteria: (1) non-English literature; (2) non-human studies (animal or cadaver); (3) review articles, case reports, and poster abstracts.

When the inclusion criteria were unclear based on the abstract and title alone, the study was included for full-text review. Articles selected for full-text review were once again screened independently by two reviewers, in duplicate. The publications were scrutinized using the same inclusion and exclusion criteria mentioned above. However, papers excluded at this level of the study also had a corresponding reason for exclusion. In the case of disagreements, a discussion between the two reviewers and the primary author (H. T.) took place.

Data Extraction: For all studies included following the full-text review, each paper was extracted independently by two reviewers, in duplicate. Data extracted included the journal name, journal impact factor from Clarivate Analytics, year of publication, total citations from Google Scholar, total number of authors, source of funding (government, institutional, philanthropic, industry), patient number, intervention in the active and control groups, the primary outcome, and conflict of interest statement. For data management purposes, data was extracted using Microsoft Excel (Redmond Wash.).

Quality Assessment: Each paper was assessed for risk of bias independently by two reviewers, in duplicate (4 reviewers in total). The ROBINS-1 tool — a tool developed to assess risk of bias in non-randomized studies of interventions — was used to assess the quality of papers included in this systematic review (11). Bias due to confounding, selection of participants into the study, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of the reported result were the domains used by the ROBINS-1 tool to assess study quality. The total score of the scale can be identified as one of four quality ratings: low, moderate, serious and critical risk of bias.

Statistical Analysis: All statistical analyses were performed using the R statistical language (version

4.0.3) (12). Descriptive statistics were calculated using median and interquartile range for continuous and frequency and percentage for categorical variables. The outcome of interest is the overall risk of bias; the tool classifies the studies into low risk, moderate risk, serious risk, or critical risk. For easier interpretation and analysis, the studies were regrouped into two levels; low/moderate and serious/critical risk. We examined the association of these two levels of the risk category with each of the following factors: sample size, number of authors, number of citations, impact factor, conflict of interest (yes/no), and source of funding (non industrial, industrial, or not reported) using univariate logistic regression. We assessed the assumptions of the logistic regression using plots and diagnostic testing. All assumptions were met. Odds ratio and 95% confidence interval (CI) of the regression were reported. Correlation between these different factors was also assessed using Spearman’s rank order correlation.

Results

Search Results: Following the removal of 459 duplicates, 1668 abstracts and titles were preliminarily screened. Of these studies, 66 full-texts were further assessed for eligibility, whereas 38 were determined to be eligible for inclusion (13-51). Search results have been summarized in a PRISMA flow chart (Figure 1).




Figure 1: PRISMA flow diagram of screened, included or excluded studies

Study Characteristics: The study characteristics have been summarized in Table 1.

Table 1: The description of PMS study characteristics published between (2010, 2021) which met the eligibility criteria (n=38)

Variable	Value
Sample size of the study; median (IQR)	39.0 (23.2, 77.2)
Number of Authors; median (IQR)	5.0 (4.0, 6.0)
Number of citations; median (IQR)	8.0 (2.2, 20.0)
Impact factor; median (IQR)	1.6 (0.8, 2.4)
Funding source; n (%)	
Not industrial	14 (36.8)
Industrial	11 (28.9)
Not Reported	13 (34.2)
Conflict of interest; n (%)	
Yes	13 (34.2)
No	25 (65.8)

IQR= Interquartile range

Fourteen studies (36.8%) received government, philanthropic, and institutional funding, while 13 studies (34.2%) did not report a source of funding. Eleven studies (28.9%) received funding from industrial sources. No conflict of interest was reported by the majority of studies (n=25; 65.8%), with the remaining articles including a clear conflict

of interest statement (n=13; 34.2%). The primary outcome most frequently evaluated was the reduction of PMS symptoms (n=19; 50%), with the other studies reporting alternative primary outcomes.

Quality Assessment: The methodological quality of the included non-randomized studies was evaluated using the ROBINS-1 tool. Guided by the seven domains of the ROBINS-1 tool, overall risk of bias score of low, moderate, serious or critical was given to each study (appendix S2). Of the 38 studies meeting inclusion, 2 were of low risk (n=2; 5.3%), 10 were of moderate risk (n=10; 26.3%), 22 were of serious risk (n=22; 57.9%), and 4 were of critical risk (n=4; 10.5%). The most common domains which resulted in a downgrade in the risk of bias score were biased due to confounding, missing data, and bias in the measurement of outcomes. To increase the sample size for analysis, the studies were regrouped into two levels; low/moderate and serious/critical risk; 12 studies were of low/moderate risk (n=12; 31.6%) and 26 were of serious/critical risk (n=26; 68.4%).

Factors associated with the Risk of bias: The distribution of characteristics of studies based on methodological quality (ROBINS-1 tool) is summarized in Table 2, with the results of the logistic regression shown in Table 3.

Table 2: The distribution of characteristics of studies based on methodological quality (ROBINS-1 tool)

Variable	n	low/moderate (n=12)	serious/critical (n=26)
Sample size, median (IQR)	38	58.00 (28.50, 87.00)	37.50 (23.00, 76.00)
Number of authors, median (IQR)	38	6.00 (4.00, 7.00)	4.00 (3.00, 5.00)
Number of citations, median (IQR)	38	12.00 (4.75, 34.25)	7.50 (2.00, 17.00)
Impact factor, median (IQR)	38	2.72 (1.97, 3.28)	1.05 (0.45, 1.70)
Source of funding, n (%)	38		
Not industrial		7 (58.3)	7 (26.9)
Industrial		4 (33.3)	7 (26.9)
Not reported		1 (8.3)	12 (46.2)
Conflict of interest, n (%)	38		
No		7 (58.3)	18 (69.2)
Yes		5 (41.7)	8 (30.8)
Year of publication-numeric, median (IQR)	38	2013.50 (2011.00, 2014.75)	2015.00 (2013.00, 2017.00)
Year of publication categorical, n (%)	38		
2010		2 (16.7)	3 (11.5)
2011		2 (16.7)	1 (3.8)
2012		1 (8.3)	1 (3.8)
2013		1 (8.3)	4 (15.4)
2014		3 (25.0)	2 (7.7)
2015		0 (0.0)	4 (15.4)
2016		0 (0.0)	3 (11.5)
2017		1 (8.3)	6 (23.1)
2018		2 (16.7)	2 (7.7)

Table 3: The logistic regression results for serious/critical risk of bias vs low/moderate risk of bias (n=38)

Variable	Univariate coefficient	Univariate OR (95% CI)	P value
Sample size of the study	0.002	1.00 (1.00, 1.01)	0.520
Number of authors	-0.43	0.65 (0.43, 0.99)	0.046
Number of citations	-0.04	0.96 (0.92, 1.01)	0.089
Impact factor	-1.60	0.20 (0.07, 0.58)	0.003
conflict of interest (Yes vs No)	-0.47	0.62 (0.15, 2.57)	0.512
Source of funding (Reference= Not industrial)			0.105
Industrial	0.56	1.75 (0.35, 8.80)	0.497
Not reported	2.49	12.00 (1.21, 118.89) ¹	0.034

¹ Very wide confidence interval (imprecise estimate because of the low sample size)

The results of the univariate regression analysis showed that an increase in the number of authors by one would decrease the odds of serious/critical risk of bias by 35% (OR=0.65; 95% CI, 0.43 to 0.99; p=0.046). The impact factor also showed an evident association, where a one unit increase in the impact factor will decrease the odds of serious/critical risk by 80% (OR=0.20; 95% CI, 0.07 to 0.57; p= 0.003). The other factors did not show evidence of association with the risk of bias levels. Although the overall association of the source of funding with the risk of bias was not evident significant (p>0.05), those who did not report any source of funding did show an association with the risk of bias. However, this association showed a wide confidence interval due to the small sample size (n=13) (OR=12.00; 95% CI, 1.21 to 118.89, p=0.03); due to the wide interval generated from a small sample, we are cautious not to interpret this finding.

Discussion

This is the first systematic review to assess the risk of bias in non-randomized studies of interventions for PMS. We hypothesized that the authors' conflicts of interest statement, a lower journal impact factor, a lower number of citations, and studies that received funding from industry sources will be associated with a greater risk of bias. Our findings revealed that a lower journal impact factor was in fact associated with a greater risk of bias. Reassuringly, the number of citations, conflict of interest statements, and funding from industry sources were not associated with a greater risk of bias. Beyond the *a priori* hypothesis, an association between the number of authors and the risk of bias was found.

RCTs are recognized as the highest level of evidence in clinical medicine for non-review studies, playing a crucial role in informing policy generation, clinical practice, and patient care (8). However,

randomization is not always possible - particularly relevant in the context of PMS - impacting the ability to use evidence to guide evidence-based clinical care. Fortunately, not all NRSs suffer from a significant amount of bias, and when carefully designed, can imitate randomization and yield valid results. The ROB assessment performed in this systematic review found that a third of the studies were of a low/moderate risk of bias, with their conclusions not being limited by confounding, missing data, and biased outcome assessments. However, the remaining two thirds of studies were of high/critical risk of bias. If these biased studies are used to inform clinical practice or policy generation, substantial negative effects on populations and individual patients can then potentially be observed. The analysis performed in the systematic review estimated the associations between ROB and factors including sample size, number of authors, conflicts of interest statement, journal impact factor, number of citations, and funding to inform clinicians and policy makers which studies are more likely to have a higher quality of evidence.

There was no evidence of an association between the number of citations and the ROBINS-1 risk of bias score. The above finding is concerning as citations are used in clinical research to support or refute new research findings. This may indicate that authors of PMS research are not properly evaluating the studies they are citing, acting as a further barrier to evidence-based care for those suffering from PMS. Alternatively, the absence of an association between citation number and ROB score may be attributed to the scope (2010-present) of our systematic review. PMS studies from 2010 are more likely to have a higher number of citations as compared to more recently published studies, regardless of the quality of evidence. However, an evident relationship between the study impact factor and ROBINS-1 risk of bias score was found. An increase in the impact factor was

associated with a lower risk of serious and critical bias ($p=0.003$). This suggests that OB/GYN journals associated with a higher impact factor are more likely to publish PMS non-randomized studies with a higher quality of evidence. The conclusion is further supported by findings in another study by Saha et al. which found that clinicians and researchers consider impact factor as a reasonable indicator of study quality ($r^2 = 0.82$, $P = 0.001$) (51).

Non-randomized studies funded by industrial sources were not methodologically less rigorous when compared with non-randomized studies funded by governmental, philanthropic or institutional sources ($p=0.497$). This suggests that the source of funding cannot be used as a reliable marker of the quality of evidence for PMS studies. However, an important, but uninterpretable, association was found between the ROBINS-1 risk of bias score and studies which did not report a source of funding ($p=0.034$). Although cautious not to interpret this finding, the primary author of our systematic review did contact the authors with available contact information to retrieve further data. Of the four responses, three authors stated that their project did not receive any funding. This may indicate that a lack of funding can manifest into a decrease in the quality of evidence of a study, where increased funding should be allocated to PMS research to bolster evidence for patient care.

Similarly, no evidence was found for an association between the ROBINS-1 risk of bias score and the dichotomous conflict of interest statement. This suggests that the conflict-of-interest statement cannot be used as a reliable marker of the quality of evidence for PMS studies. However, the lack of association between the two variables could be attributed to the frequent dichotomization of the variable. A qualitative value of “no” can be attributed to a study either if (1) the author explicitly indicates that there are no conflicts of interest, or (2) no conflict of interest statement is explicitly stated in the study. In order to properly assess this factor, PMS studies should push to be transparent with their conflicts of interest.

Beyond the a priori hypothesis, our systematic review also found a significant association between the ROBINS-1 risk of bias score and the number of authors in the study. The number of authors on low/moderate studies was on average higher than the number of authors on serious/critical studies ($p=0.046$). This suggests that PMS studies with a higher number of authors are more likely to have a

higher quality of evidence. This finding may be linked to the phenomenon of “knowledge diffusion”. By increasing the number of authors, a study can increase its faculty representation and the attention it receives, resulting in increased credibility and theoretical quality of evidence (52). Lastly, no association was found between sample size and ROBINS-1 risk of bias ($p=0.52$). This suggests that larger sample sizes cannot be used as a reliable marker of the quality of evidence for PMS studies.

It is important to recognize that the following associations are influenced by the number of studies that met the inclusion criteria ($n=38$) - the most significant limitation of our systematic review. In statistical analysis, a smaller sample size decreases statistical certainty in the results, manifesting as a large confidence interval. With a larger confidence interval, it is more likely for the confidence interval to include a value of “1”, rendering an association statistically insignificant. Greater sample size may thus reveal further associations between the ROBINS-1 risk of bias tool and different study factors.

Conclusion

Our systematic review concludes that the methodological rigor of non-randomized studies of PMS can vary, with the quality of evidence most usually limited by bias due to confounding, missing data, and bias in the measurement of outcomes. Non-randomized studies which had fewer authors and a lower impact factor were associated with a decreased quality of evidence. However, in our current assessment, no significant association was found between the ROBINS-1 risk of bias score and the number of citations, the sample size, the funding type, or the conflict of interest statement.

Conflict of Interests

Authors have no conflict of interests.

Acknowledgments

There is no conflict of interest among the authors.

References

1. Fernández MDM, Saulyte J, Inskip HM, Takkouche B. Premenstrual syndrome and alcohol consumption: a systematic review and meta-analysis. *BMJ Open* 2018; 8: e019490.
2. Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and

- burden of illness. *Expert Rev of Pharmacoeconomics & Outcomes Res* 2009; 9: 157–70.
3. O'Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMO Montreal consensus. *Arch Womens Ment Health* 2011; 14: 13–21.
 4. Jarosz AC, Jamnik J, El-Soheby A. Hormonal contraceptive use and prevalence of premenstrual symptoms in a multiethnic Canadian population. *BMC Women's Health* 2017; 17: 87.
 5. Halbreich U, Backstrom T, Eriksson E, O'Brien S, Calil H, Ceskova E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. *Gynecol Endocrinol* 2007; 23: 123–30.
 6. Reeves BC. Principles of research: limitations of non-randomized studies. *Surgery (Oxford)* 2008; 26: 120–4.
 7. Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies. *Hepatology* 2006; 44: 1075–82.
 8. Odierna DH, Forsyth SR, White J, Bero LA. The cycle of bias in health research: a framework and toolbox for critical appraisal training. *Account Res* 2013; 20: 127–41.
 9. Naci H. What to do (or not to do) when randomization is not possible. *J Heart Lung Transplant* 2017; 36: 1174–7.
 10. Moher D, Liberati A, Tetzlaff J, G Altman D, Prisma Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; 339: b2535.
 11. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; 12; 355: i4919.
 12. R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.r-project.org/index.html>
 13. Anil A, Peker T, Göktaş T, Kilic S, Erbaş D. Importance of acupuncture on premenstrual syndrome. *Clin Exp Obstet Gynecol* 2012; 39: 209–13.
 14. Anwar S, Shami N, Asif S. Use of Low Dose Danazol in Luteal Phase Only as Management of Premenstrual Syndrome and Mastalgia. *PJMHS* 2015; 9.
 15. Bakay.K, Ulubaşoğlu H, Atan T, Alaçam H, Güven D, Batioğlu S. The effect of physical activity on the levels of the hormones, serotonin and melatonin in premenstrual syndrome. *Clinical and Experimental Obstetrics & Gynecology* 2018; 10: 425–7.
 16. Bertone-Johnson ER, Chocano-Bedoya PO, Zagarins SE, Micka AE, Ronnenberg AG. Dietary vitamin D intake, 25-hydroxyvitamin D3 levels and premenstrual syndrome in a college-aged population. *J Steroid Biochem Mol Biol* 2010; 121: 434–7.
 17. Chai N, Wu Y, Zhang M, Wu W-B, Zhang H, Kong F-W, et al. Remote intervention using smartphone for rural women suffering from premenstrual syndrome: A propensity score matched analysis. *Medicine (Baltimore)* 2018; 97: e11629.
 18. Chen BF, Powell MC, O'Beirne C. An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome. *J Obstet Gynaecol* 2017; 37: 645–8.
 19. Chung M-S, Kim G-H. Effects of *Elsholtzia splendens* and *Cirsium japonicum* on premenstrual syndrome. *Nutr Res Pract* 2010; 4: 290–4.
 20. Crow E, Jeannot E. Premenstrual syndrome: Symptomatic and diagnosed prevalence, dualistic treatment approach – A cross-sectional study in Ukraine. *Int J Prev Med* 2017; 8: 66.
 21. Danno K, Colas A, Terzan L, Bordet M-F. Homeopathic treatment of premenstrual syndrome: a case series. *Homeopathy* 2013; 102: 59–65.
 22. Ekenros L, Hirschberg AL, Bäckström T, Fridén C. Postural control in women with premenstrual symptoms during oral contraceptive treatment. *Acta Obstet et Gynecol Scand* 2011; 90: 97–102.
 23. ama CRB, Lasmar R, Gama GF, Oliveira L, Ribeiro MG, Geller M. Premenstrual syndrome: Clinical assessment of treatment outcomes following *Borago officinalis* extract therapy. *Revista Brasileira de Medicina* 2014; 71: 211–217.
 24. Can Gürkan Ö, Türk Öğün S, Potur DK, Kömürçü N. The Effect of A Sleep Hygiene Interventions in Women with Premenstrual Syndrome. *Zeynep Kamil Tıp Bülteni* 2017; 48: 162–7.
 25. Horbatiuk O, Binkovska A, Herych O, Ropotan A, Zhytko N, Mandziy I, et al. Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome. *Current Issues in Pharmacy and Medical Sciences* 2017; 30: 138–41.
 26. Itsekson AM, Soriano D, Zolti M, Seidman DS, Carp HJA. Intradermal sex hormone desensitization for relief of premenstrual symptoms may improve the obstetric outcome of women with recurrent pregnancy loss. *Gynecol Endocrinol* 2013; 29: 169–72.
 27. Jang D, Kim MD, Lee SJ, Kim IJ, Park SI, Won JY, et al. The Effect of Uterine Artery Embolization on Premenstrual Symptoms in Patients with Symptomatic

- Fibroids or Adenomyosis. *J Vasc and Interv Radiol* 2014; 25: 833-38.
28. Johnny M, Kumar SS, Rajagopalan A, Mukkadan JK. Vestibular stimulation for management of premenstrual syndrome. *J Nat Sci Biol Med* 2017; 8: 82–6.
 29. Kamagata E, Yamada K. Improvements in Quality-Adjusted Life Years and Cost-Utility after Pharmacotherapy for Premenstrual Dysphoric Disorder: A Retrospective Study. *Clin Drug Investig* 2018; 38: 49-55.
 30. Klein-Laansma CT, Jansen JCH, van Tilborgh AJW, Van der Windt DAWM, Mathie RT, Rutten ALB. Semi-standardised homeopathic treatment of premenstrual syndrome with a limited number of medicines: Feasibility study. *Homeopathy* 2010; 99: 192–204.
 31. Lamarche LJ, Driver HS, Forest G, De Koninck J. Napping during the late-luteal phase improves sleepiness, alertness, mood and cognitive performance in women with and without premenstrual symptoms. *Sleep and Biological Rhythms* 2010; 8: 151–9.
 32. Lukes AS, McBride RJ, Herring AH, Fried M, Sherwani A, Dell D. Improved Premenstrual Syndrome Symptoms after NovaSure Endometrial Ablation. *J Minim Invasive Gynecol* 2011; 18: 607–11.
 33. Maddineshat M, Keyvanloo S, Lashkardoost H, Arki M, Tabatabaiechehr M. Effectiveness of Group Cognitive-Behavioral Therapy on Symptoms of Premenstrual Syndrome (PMS) . *Iran J Psychiatry* 2016; 11: 30–6.
 34. Marcinko I, Torjanac M. The Difference in the Severity of Premenstrual Symptoms between Users and Non-users of Oral Contraceptives. *Coll Antropol* 2015; 39: 855–62.
 35. Merki-Feld GS, Hund M. Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use. *The European Journal of Contraception & Reproductive Health Care* 2010; 15: 413-22.
 36. Momoeda M, Sasaki H, Tagashira E, Ogishima M, Takano Y, Ochiai K. Efficacy and Safety of Vitex agnus-castus extract for Treatment of Premenstrual Syndrome in Japanese Patients: A Prospective, Open-label Study. *Adv Ther* 2014 Mar; 31: 362–73.
 37. Norouzi Javidan A, Haghollahi F, Ramezanzadeh F, Yekaninejad MS, Amiri Z, Noroozi M, et al. Effects of ethinyl estradiol plus desogestrel on premenstrual symptoms in Iranian women. *Acta Med Iran* 2014; 52: 837–43.
 38. Nyberg S. Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol. *Contraception* 2013; 87: 773–81.
 39. Pang Y, Liu H, Duan G, Liao H, Liu Y, Feng Z, et al. Altered Brain Regional Homogeneity Following Electro-Acupuncture Stimulation at Sanyinjiao (SP6) in Women with Premenstrual Syndrome. *Front Hum Neurosci* 2018; 12: 104.
 40. Scordalakes C, delRosario R, Shimer A, Stankiewicz R. Efficacy and patient satisfaction after NovaSure and Minerva endometrial ablation for treating abnormal uterine bleeding: a retrospective comparative study. *Int J Womens Health* 2018; 10: 137–45.
 41. Segeblad B, Bannbers E, Moby L, Nyberg S, Bixo M, Bäckström T, et al. Allopregnanolone serum concentrations and diurnal cortisol secretion in women with premenstrual dysphoric disorder. *Arch Womens Ment Health* 2013; 16: 131–7.
 42. Sharma B, Misra R, Singh K, Sharma R, Archana null. Comparative study of effect of anuloma-viloma (pranayam) and yogic asanas in premenstrual syndrome. *Indian J Physiol Pharmacol* 2013; 57: 384–9.
 43. Steinberg EM, Cardoso GMP, Martinez PE, Rubinow DR, Schmidt PJ. Rapid response to fluoxetine in women with premenstrual dysphoric disorder. *Depress Anxiety* 2012; 29: 531–40.
 44. Takeda T, Imoto Y, Nagasawa H, Takeshita A, Shiina M. Fish Consumption and Premenstrual Syndrome and Dysphoric Disorder in Japanese Collegiate Athletes. *J Pediatr Adolesc Gynecol* 2016; 29: 386–9.
 45. Takeda T, Kondo A, Koga S, Hayakawa J, Hayakawa K, Hiramatsu K, et al. Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: Open-label pilot study: Ethinylestradiol/drospirenone for PMS. *J Obstet Gynaecol Res* 2015; 41: 1584–90.
 46. Tjandrawinata RR, Nofiarny D, Susanto LW, Hendri P, Clarissa A. Symptomatic treatment of premenstrual syndrome and/or primary dysmenorrhea with DLBS1442, a bioactive extract of *Phaleria macrocarpa*. *Int J Gen Med* 2011; 4: 465–76.
 47. Tsai F-H, Chu I-H, Lin T-Y, Liang J-M, Hsu H-T, Wu W-L. Preliminary evidence on the effect of Yoga on the reduction of edema in women with premenstrual syndrome. *European Journal of Integrative Medicine* 2017; 9: 63–8.
 48. Tsai SY. Effect of Yoga Exercise on Premenstrual Symptoms among Female Employees in Taiwan. *Int J Environ Res Public Health* 2016; 13: 721.
 49. Wu W-L, Lin T-Y, Chu I-H, Liang J-M. The Acute Effects of Yoga on Cognitive Measures for Women with Premenstrual Syndrome. *J Altern Complement Med* 2015; 21: 364–9.

50. Zhang H, Zhu M, Song Y, Kong M. Baduanjin exercise improved premenstrual syndrome symptoms in Macau women. *J Tradit Chin Med* 2014; 34: 460–4. 1195–225.
51. Saha S, Saint S, Christakis DA. Impact factor: a valid measure of journal quality? *J Med Libr Assoc.* 2003; 91: 42–6.
52. Tahamtan I, Safipour Afshar A, Ahamdzadeh K. Factors affecting number of citations: a comprehensive review of the literature. *Scientometrics* 2016; 107:

Citation: Tehfe H, Chow R, Li S, Kim P, Samari S, Hayawi L, et al. **Risk of Bias Assessment in Non-Randomized Studies of Interventions for Premenstrual Syndrome: A Systematic Review.** *J Family Reprod Health* 2022; 16(2): 93-101.